厚生労働科学研究費補助金 (創薬基盤推進研究事業)
分担研究報告書

新興・再興感染症に対するヒトM細胞標的型粘膜ワクチン開発に関する研究

研究分担者：奥野良信
（財）阪大微生物病研究会観音寺研究所　所長

研究要旨
　昨年度の本研究において、インフルエンザ HA ワクチンをマウスの腸管に免疫した場合、インフルエンザウイルス特異的な鼻粘膜 IgA 抗体や血中 IgG 抗体を感染防御レベル以上まで誘導できることを明らかにした。今回、このマウスから抗インフルエンザモノクローナル（IgA）抗体を作製し、得られたクローンの性状について解析を行った。
20 種類の IgA モノクローナル抗体が得られ、このうち 8 種類は、中和活性を有していることが分かった。このことから、インフルエンザワクチンを腸管免疫することにより、鼻粘膜上に中和活性をもつ IgA 抗体を誘導できることが示唆された。今後、腸管へのデリバリーシステムを構築できれば、インフルエンザ HA ワクチンを抗原とする粘膜ワクチンの開発に結びつくと考えられた。

A. 研究目的

腸管粘膜に存在するM細胞を標的とするインフルエンザワクチンの開発を目的とし、インフルエンザウイルスの至適抗原の検索を行っている。昨年度の研究において、インフルエンザ HA ワクチンをマウスの腸管に直接免疫することにより、インフルエンザウイルス特異的な鼻粘膜 IgA や血中 IgG 抗体を誘導することができた。今回はこのマウスから抗インフルエンザモノクローナル（IgA）抗体を作製し、その性状について解析を行った。

B. 研究方法

昨年度の本研究において、A/Solomon Islands/3/2006(H1N1)株のインフルエンザ HA ワクチンを BALB/c マウス（雌、10～11 週齢）に投与した。投与量は、500 μg/匹とし、ゾンデを用いて胃内に直接投与する方法によって 2～3 週間隔で 4 回免疫を行った。なお、最初の 3 回の免疫にはアジュバントとして精製百日咳毒素を 40 μg/匹を添加した。4 回目の免疫から 3 日後に、鼻腔洗浄液と血清を回収し、鼻空洗浄液からはインフルエンザウイルス特異的 IgA-ELISA 抗体価を、血清からは特異的 IgG-ELISA 抗体価を調べた。その結果、いずれの抗体価も感染防御レベルを十分に超えていることが分かった。

今回、サブクラスが IgA のインフルエンザウイルス特異的モノクローナル抗体を作製することを目的とし、この個体から脾臓細胞を取り出して、マウスミエローマ細胞（SP-2/0-Ag14）と細胞融合させ、ハイブリドーマ細胞を作製した。ハイブリドーマ細胞のスクリーニングは、ELISA 法で行い、固相化抗原には A/Solomon Islands 株の HA ワクチンを、二次抗体には抗マウス IgA 抗体（HRPO 標識）を用いた。

定法に従って、抗インフルエンザウイルスモノクローナル（IgA)抗体を作製し、得られたクローンについて、HI 試験、間接蛍光抗体法（IFA）、中和試験、ELISA 試験を実施し、その性状解析を行った。

(倫理面への配慮)

本研究の目的のために実施される動物実験計画は、（財）阪大微生物病研究会観音寺研究所の動物実験委員会への申請をもとに、倫理面を含む審査・承認を受けた。また、本実験は「研究機関等における動物実験等の実施に関する基本指針」（文部科学省告示第 71 号平成 18 年 6 月 1 日）に基づく研究施設の動物実験ガイドラインに則り、動物の保定法・麻酔の方法・接種法・飼育観察法など、実験動物に対しての苦痛を可能な限り軽減できる方法で実施した。

C. 研究結果

A/ Solomon Islands 株インフルエンザ HA ワクチンで腸管免疫されたマウスから、20 種類のインフルエンザウイルス特異的 IgA モノクローナル抗体を得た（表）。このうち、8 種類の抗体は、HI 活性、IFA、中和活性の全てが陽性であったことから、これらは HA 蛋白質に対する抗体であると考えられた。一方、IFA が陽性で、HI 活性と中和活性が陰性の抗体は 5 種類あり、また、全て陰性の抗体は 7 種類あった。これらは、HA 蛋白質以外のウイルス蛋白質を認識する抗体であると推測される。インフルエンザ HA ワクチンは、主な成分として HA 蛋白質を含有するが、NP、M、および NA 蛋白質なども含むことが知られており、これらに対する抗体の可能性がある。

抗体クローン番号	HI	IFA	中和	ELISA		
				A/PR8	A/NC	A/Bris
1	−	+	−	71%	73%	100%
2	−	−	−	107%	99%	91%
3	+	+	+	5%	52%	100%
4	+	+	+	5%	51%	105%
5	−	−	−	87%	83%	100%
6	−	−	−	114%	108%	94%
7	+	+	+	6%	16%	87%
8	+	+	+	6%	74%	90%
9	−	−	−	110%	111%	92%
10	+	+	+	6%	24%	87%
11	−	+	−	84%	83%	97%
12	−	+	−	13%	21%	20%
13	−	+	−	12%	21%	20%
14	−	−	−	101%	103%	92%
15	+	+	+	7%	52%	69%
16	+	+	+	5%	84%	84%
17	−	+	−	88%	82%	108%
18	+	+	+	5%	5%	5%
19	−	−	−	104%	99%	108%
20	−	−	−	77%	71%	92%

表 1. 各種アッセイにおける反応性

A/PR8: A/Pueruto Rico/8/34, A/NC: A/New Caledonia/20/99, A/Bris: A/Brisbane/59/2007

次に、これら 20 種類のモノクローナル抗体の交差反応性を調べるために、A/Solomon Islands 株 HA ワクチンだけでなく、過去の H1N1 ウイルスの HA ワクチン（A/Puerto Rico/8/34、A/ New Caledonia/20/99、A/ Brisbane/59/2007）を ELISA プレートにそれぞれ固相化し（100ng/well)、ELISA 試験を実施した。A/Solomon Islands 株との反応性を、100%とした場合の相対値を表に示す。その結果、HA 蛋白質を認識すると推測される 8 種類の抗体は、他のワクチン株との交差性が低く、特に A/Puerto Rico 株との反応性の低さは顕著であった。A/Solomon Islands 株は 2007/2008 シーズンの製造株であるのに対し、A/ Puerto Rico 株は 1950/1951- 1954/1955 シーズンの製造株であることから、これは抗原性の変化が原因と考えられる。

逆に、中和活性を有しない 12 種類の抗体のうちの多くは、他のワクチン株との交差性が高かった。このことからも、これらは、NP や M 蛋白質などの抗原変異の起こりにくい蛋白質に対す

る抗体であると推測された。

D. 考察

昨年度の本研究では、インフルエンザ HA ワクチンを直接腸管に免疫することにより、感染防御レベルを超えるインフルエンザウイルス特異的な鼻粘膜 IgA や血中 IgG 抗体を誘導できることを報告した。今回の試験においては、この免疫方法で、中和活性を持つ IgA 抗体を誘導できることが明らかになった。これらのことから、インフルエンザワクチンを腸管免疫することにより、鼻粘膜上に中和活性をもつ IgA 抗体を誘導できることが示唆された。

今後、腸管へのデリバリーシステムが構築できれば、インフルエンザ HA ワクチンを抗原とする粘膜ワクチンの開発に結びつくと考えられた。

E. 結論

インフルエンザ HA ワクチンを直接腸管に免疫することにより、インフルエンザウイルスに対する中和活性を持つ鼻粘膜 IgA を誘導することができた。

F. 健康危機情報

特記事項なし

G. 研究発表

1. 論文発表
   なし
2. 学会発表
   なし

H. 知的財産権の出願・登録状況 (予定を含む)

1. 特許取得
   なし
2. 実用新案登録
   なし
3. その他
   なし

厚生労働科学研究費補助金 (創薬基盤推進研究事業)
研究分担報告書

B細胞亜集団の分化・活性化機構の研究

研究分担者：紅露　拓
独立行政法人医薬基盤研究所
免疫応答制御プロジェクト・プロジェクトリーダー

研究要旨
経鼻ワクチン投与のメリットの一つに変異病原体に対する交叉防御能の誘導が挙げられる。B細胞亜集団のひとつであるB-1細胞は様々な病原体に対する反応性を持ち、粘膜面のIgA抗体産生にも関与していることが知られている。そこでB-1細胞を欠損するBtkノックアウトマウスの解析とB-1細胞再構築実験により、経鼻ワクチン応答にB-1細胞が関与することが明らかとなった。

A. 研究目的

経鼻ワクチン投与は非侵襲的であること、粘膜表面に防御抗体を誘導できること、変異病原体に対する交叉防御能が得られることが代表的なメリットである。動物実験において経鼻ワクチン投与にはアジュバントの併用が必須であるが、嗅神経を通じた中枢神経への移行による副作用の問題などにより臨床応用が遅れている。また、なぜ経鼻免疫時にのみ、変異病原体に対する交叉防御能が誘導されるのかも明らかにされていない。

B-1細胞はB細胞亜集団の一つで自然抗体を産生するほか、粘膜IgAの産生にも関わっている。また、自然抗体はインフルエンザウイルスを含む様々な病原体に反応性を持つことが報告されている。鼻粘膜IgAを産生する細胞が明らかになれば、交叉防御能の獲得機構が明らかになるだけでなく、その細胞を標的とした新規経鼻ワクチンアジュバントの開発も見込まれる。

そこでB-1細胞の経鼻ワクチン応答への関与について検討した。

B. 研究方法

B-1細胞と自然抗体を欠損するBtkノックアウトマウスおよび対照群、あるいはBALB/c nu/nuマウスおよび対照群をペントバルビタール系麻酔薬の腹腔内投与により麻酔し、HA抗原として1μgのインフルエンザスプリットワクチン原液（A/Brisbane/59/2007(H1N1)）を10 μgのpoly(I:C)あるいは最終濃度0.5%のChitosanとともに点鼻投与した。投与量は片鼻5 μlずつとした。２週間後に同様の処置を行ない、さらに２週間後にマウスを安楽殺し、血清および鼻腔洗浄液を回収した。一部の実験では1μgの同じワクチンを同じスケジュールでアジュバントを併用せずに皮下投与した。

BtkノックアウトマウスにB6.SJLマウスd15胎児肝から精製した血球系列マーカー陰性、c-kit陽性、IL-7受容体a鎖陽性共通リンパ球前駆細胞（CLP）を移植し、８週間後に上記スケジュールにて経鼻インフルエンザワクチン投与を行なった

鼻腔洗浄液および血清サンプル中のインフルエンザウイルスHA抗原に対する

抗体価は希釈したスプリットワクチン原液をプレートに固相化したELISA法にて検出した。

(倫理面への配慮)

動物実験は医薬基盤研究所実験動物取扱規定に準じ、動物実験委員会の承認を受けた上で行ない、動物の苦痛が必要最小限となるよう配慮した。遺伝子組換え生物については医薬基盤研究所組換えDNA実験委員会の承認を得た上で、適切な封じ込め環境下で行なった。

C. 研究結果

アジュバントにpoly(I:C)を使い、インフルエンザワクチンを経鼻投与すると、対照群マウスでは鼻腔洗浄液中に抗HA-IgA抗体が検出されたが、Btkノックアウトマウスでは検出されなかった。対照群では血清中に抗HA IgG1, IgG3, IgAの各抗体が検出されたが、Btkノックアウトマウスではいずれも検出されなかった。アジュバントにchitosanを用いてワクチン経鼻投与を行なった場合、対照群では鼻腔洗浄液中抗HA IgA抗体、血清IgG1, IgG3, IgA抗体が検出されたが、Btkノックアウトマウスではこれらのうち血清抗HA IgG1抗体がわずかに検出されただけであった。

B6.SJLマウス胎児肝CLPを移植したBtkノックアウトマウスでは移植8週後に血清IgM, IgG3がC57BL/6マウスと同等の価に上昇した。これらのマウスの経鼻免疫後の鼻腔洗浄液中には抗HA IgA抗体が無処置のBtkノックアウトマウスと比べ有意に高く検出された。また、腹腔細胞中のドナー由来細胞（CD45.1陽性）のほとんどがB-1細胞であった。

経鼻インフルエンザワクチン応答にT細胞が関与しているか調べるためにヌードマウスに1 μgのインフルエンザワクチンを10 μgのpoly(I:C)とともに経鼻投与した際には鼻腔洗浄液中の抗HA IgA抗体、血清中の抗HA IgG, IgA抗体は全く検出されなかった。

D. 考　察

Btkノックアウトマウスが経鼻免疫応答に反応しないことが初めて明らかになった。Btkノックアウトマウスは B-1細胞およびそれに由来する自然抗体の欠損があり、経鼻免疫応答にB-1細胞および自然抗体が関与している可能性がある。

一方、アジュバントに用いたpoly(I:C)のシグナル伝達経路にBtkが関わっているという報告はないが、Btkに点変異のあるCBA/Nマウスの脾細胞はpoly(I:C)刺激時の増殖応答が悪いこと、Btkは樹状細胞にも発現することが報告されており、アジュバントが働いていない可能性も考えられた。しかし、poly(I:C)とは異なる作用機序を持つと考えられるchitosanをアジュバントとして用いてもBtkノックアウトマウスは経鼻免疫に不応答であることから、B-1細胞の欠損がその原因である可能性が支持される。

そこでBtkノックアウトマウスに正常B-1細胞を移入して経鼻免疫応答が回復するか調べた。我々は胎児肝のCLPがB-1細胞に偏った分化能を持つことを見いだしており、野生型マウス胎児肝CLPをBtkノックアウトマウスに移植することにより、B-1細胞を再構築した。またドナーにB6.SJLマウスを使うことによりCD45アロタイプによるドナー細胞の識別ができるようにした。移植を受けたBtkノックアウトマウスはB-1細胞の再構築と自然抗体価の上昇が見られ、経鼻免疫応答も部分的に回復したため、B-1細胞および自然抗体が経鼻免疫応答に重要であることが初めて明らかとなった。

B-1細胞の特徴として一部の抗原に対しT細胞非依存性に抗体産生を行なうことが挙げられる。そこでインフルエンザ

ワクチンに対する経鼻免疫応答がT細胞に依存するかヌードマウスを用いて調べたところ、ヌードマウスは全く応答を示さなかったことから、インフルエンザワクチンに対する免疫応答はT細胞依存性であることが推察された。

経鼻免疫応答におけるB-1細胞の役割はそれ自身が粘膜IgA産生を担当している可能性とB-1細胞由来の自然抗体がB-2細胞による獲得免疫応答の発動に必要である可能性が考えられるが、その解明にはBtkノックアウトマウスへの野生型マウス血清の移入実験や、B-1/B-2細胞のアロタイプキメラマウスの鼻粘膜組織におけるIgA産生細胞の検出が今後必要である。経鼻免疫応答における細胞性機構の解明は新規粘膜ワクチンアジュバントの開発の手がかりとなるものである。

E. 結　論

経鼻インフルエンザワクチンに対する免疫応答はB-1細胞および自然抗体が関与し、T細胞依存性の反応であることが明らかとなった。

F. 健康危機情報

該当無し

G. 研究発表

1. 論文発表

該当無し

2. 学会発表

Participation of Bruton's tyrosine kinase in immune response to nasal influenza vaccination

KOURO Taku[1], IIDA Ryuji[1], NAGATAKE Takahiro[2], ARAKAWA Akemi[1], IKUTANI, Masashi[3], KUNISAWA Jun[2], KIYONO Hiroshi[2], TAKATSU Kiyoshi[3] (1. Lab. Immune Modulation, National Institute of Biomedical Innovation, 2. Dept. Microbiology and Immunity, The Institute of Medical Science, The Univ. Tokyo, 3. Dept. Immunobiology and Pharmacological Genetics, Univ. Toyama) 2010年　国際免疫学会（ポスター）

B-1 cell lineage specification occurs between hematopoietic stem cell and prolymphocyte stages by differentiation environments.

IIDA Ryuji[1], ARAKAWA Akemi[1], IKUTANI Masashi[2], NAGAI Yoshinori[2], TAKATSU Kiyoshi[2], KOURO Taku[1], ([1]Lab. Immune Modulation, Nat. Inst. Biomed. Innov., [2]Dept. Immunology and Pharmacological Genetics, Univ. Toyama) 2010年　国際免疫学会（口頭発表）

インフルエンザワクチン経鼻投与時の免疫応答機構の解析―ブルトン型チロシンキナーゼの関与　紅露　拓、飯田隆治、篠田香織、服部祐紀、高津聖志　２０１０年　日本ワクチン学会（口頭発表）

H. 知的財産権の出願・登録状況 (予定を含む)

1. 特許取得

該当無し

2. 実用新案登録

該当無し

3. その他

特になし

Ⅳ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表
<雑 誌>

研究分担者：清野　宏

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Obata, T., Goto, Y., Kunisawa, J., Sato, S., Sakamoto, M., Setoyama, H., Matsuki, T., Nonaka, K., Shibata, N., Gohda, M., Kagiyama, Y., Nochi, T., Yuki, Y., Fukuyama, Y., Mukai, A., Shinzaki, S., Fujihashi, K., Sasakawa, C., Iijima, H., Goto, M., Umesaki, Y., Benno, Y., and Kiyono, H.	Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis.	Proc Natl Acad Sci U S A.	107	7419-7424	2010
Tokuhara, D., Yuki, Y., Nochi, T., Kodama, T., Mejima, M., Kurokawa, S., Takahashi, Y., Nanno, M., Nakanishi, U., Takaiwa, F., Honda, T., and Kiyono, H.	Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine.	Proc Natl Acad Sci U S A.	107	8794-8799	2010
Nochi, T., Yuki, Y., Takahashi, H., Sawada, S., Mejima, M., Kohda, T., Harada, N., Kong, I.G., Sato, A., Kataoka, N., Tokuhara, D., Kurokawa, S., Takahashi, Y., Tsukada, H., Kozaki, S., Akiyoshi, K., and Kiyono, H.	Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.	Nat Mater.	9	572-578	2010
Fuglem, B., Jirillo, E., Bjerkås, I., Kiyono, H., Nochi, T., Yuki, Y., Raida, M.,	Antigen-sampling cells in the salmonid intestinal epithelium.	Dev Comp Immunol.	34	768-774,	2010

Fischer, U., and Koppang, E.O.					
Yuki, Y., Nochi, T., Harada, N., Katakai, Y., Shibata, H., Mejima, M., Kohda, T., Tokuhara, D., Kurokawa, S., Takahashi, Y., Ono, F., Kozaki, S., Terao, K., Tsukada, H., and Kiyono, H.	In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates.	J Immunol.	185	5436-5443	2010
Kayamuro, H., Yoshioka, Y., Abe, Y., Arita, S., Katayama, K., Nomura, T., Yoshikawa, T., Kubota-Koketsu, R., Ikuta, K., Okamoto, S., Mori, Y., Kunisawa, J., Kiyono, H., Itoh, N., Nagano, K., Kamada, H., Tsutsumi, Y., and Tsunoda, S.	Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.	J Virol.	84	12703-127 12	2010.
Terahara, K., Nochi, T., Yoshida, M., Takahashi, Y., Goto, Y., Hatai, H., Kurokawa, S., Jang, M.H., Kweon, M.N., Domino, S.E., Hiroi, T., Yuki, Y., Tsunetsugu-Yokota, Y., Kobayashi, K., and Kiyono, H.	Distinct fucosylation of M cells and epithelial cells by Fut1 and Fut2, respectively, in response to intestinal environmental stress.	Biochem Biophys Res Commun.	404	822-828	2011
Kim, D.Y., Sato, A., Fukuyama, S., Sagara, H., Nagatake, T., Kong, I.G., Goda, K., Nochi, T., Kunisawa, J., Sato, S., Yokota, Y., Lee, C.H., and Kiyono, H.	The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens.	J Immunol.	186	4253-62	2011

研究分担者：保富康宏

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
.Yoshida,T., Saito,A., Iwasaki,Y.,Iijima,S., Kurosawa,T., Katakai,Y., Yasutomi,Y.,Reimann,K.A., Hayakawa,T. and Akari,H.	Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity.	Frontiers Microbiol.	in press		2011
Xing, Li., Wang, J.C., Li, T-C., Yasutomi,Y., Lara,J., Khurdyakaov, Y., Schofield D., Emerson,S., Purcell,R., Takeda,N., Miyamura,T. and Holland,R.C.	Spatial configuration of hepatitis E virus antigenic domain.	J.Virol.	85	1117-1124	2011
Chono,H., Matsumoto,K., Tsuda,H., Saito,N., Lee,K.., Kim,S., Shibata,H., Ageyama,N., Terao,K., Yasutomi,Y., Mineno J., Kim,S., Inoue,M. and Kato,I.	Acquistion of HIV-1 resistance in T lymphocytes using an ACA-specific E.coli mRNA interferase.	Human Gene Ther.	22	35-43	2011
Saito,A., Nomaguchi,M., Iijima,S.,Lee,Y-J., Kono,K., Nakayama,E.E., Shioda,T., Yasutomi,Y., Adachi,A., Matano,T., Akari,H.	A novel monkey-tropic HIV-1 derivative encoding only minimal SIV sequences can replicate in cynomolgus monkeys.	Micorbes Infect	13	58-64	2011
Naruse,T.K., Zhiyong,C., Yanagida,R., Yamashita,T., Saito,Y., Mori,K., Akari,H.,	Diversity of MHC class I genes in Burmese-origine rhesus macaques.	Immunogenetics	62	601-611	2010

Yasutomi,Y., Matano,T. and Kimura,A.					
Okabayashi,S., Uchida,K., Nakayama,H., Ohno,C., Hanari,K., Goto,I. and Yasutomi,Y.	Periventricular Leucomalacia (PVL)-like lesions in two neonatal cynomolgus monkeys (macaca fascicularis)	J.Comp.Pathol.	Epub		2010
Yasuhiro Yasutomi.	Establishment of Specific Pathogen-Free Macaque Colonies in Tsukuba Primate Research Center of Japan for AIDS research.	Vaccine	B	75-77	2010
Fujimoto,K., Takano,J., Narita,T., Hanari,K., Shimozawa,N., Sankai,T., Yoshida T., Terao,K., Kurata,T. and Yasutomi,Y.	Simian Retrovirus type D infection in a colony of cynomolgus monkeys.	Comp.Med.	60	51-53	2010
Cueno,M.E., Karamatsu,K., Yasutomi, Y., Laurena,A.C. and Okamoto.T.	Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant.	Transgenic Res.	19	889-895	2010

研究分担者：奥野良信

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yunoki, M., Kubota-Koketsu, R., Urayama, T., Sasaki, T., Analiwa, D., Konoshima, Y., Ideno, S., Fukunaga, Y., Morikawa, S., Hiroi, S., Takahashi, K., Okuno, Y., Hagiwara, K., Ikuta, K.	Significant neutralizing activity of human immunoglobulin preparations against pandemic 2009 H1N1.	British J of Haematology	148	953-955	2010

Yamashita, A., Kawashita N., Kubota-Koketsu, R., Inoue, Y., Watanabe, Y., Ibrahim, MS., Ideno, S., Yunoki, M., Okuno, Y., Takagi, T., Yasunaga, T., Ikuta, K.	Highly conserved sequences for human neutralizing epitope on hemagglutinin on influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition.	BBRC	393	614-618	2010
Kanai, Y., Boonsathorn, N., Chittaganpitch, M., Bai, G., Li, Y., Kase, T., Takahashi, K., Okuno, Y.,	Jampangern, W., Ikuta, K., Sawanpanyalert, P. The impact of antigenic drift of influenza A virus on human herd immunity: Sero-epidemiological study of H1N1 in healthy Thai population in 2009.	Vaccine	28	5437-5444	2010
Sakabe S., Iwatsuki-Horimoto K., Horimoto T., Nidom CA., Quynh Le MT., Takano R., Kubota-Koketsu R., Okuno Y., Ozawa M., Kawaoka Y.	A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection	Antiviral Res	88	249-255	2010
Posadas-Herrera G., Inoue S., Fuke I., Muraki Y., Mapua CA., Khan AH., Parquet Mdel C., Manabe S., Tanishita O., Ishikawa T., Natividad FF., Okuno Y., Hasebe F., Morita K.	Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate.	Vaccine	23	7939-7946	2010

Baba K., Okuno Y., Tanaka-Taya K., Okabe N.	Immunization coverage and natural infection rates of vaccine-preventable diseases among children by questionnaire survey in 2005 in Japan.	Vaccine	In press		
Okada J., Ohshima N., Kubota-Koketsu R., Iba Y., Ota S., Takase W., Yoshikawa T., Ishikawa T., Asano Y., Okuno Y., Kurosawa Y.	Localization of epitopes recognized by monoclonal antibodies that neutralized the H3N2 influenza viruses in man.	Gen Virol.	In press		

研究成果の刊行に関する一覧表
<書　籍>

研究分担者：清野　宏

著者名	論文タイトル名	書籍全体の編集者名 書籍名	出版社名 出版地	出版年 ページ
Kunisawa, J. and Kiyono, H	Analysis of intestinal T cell populations and cytokine productions.	Stefan H.E. Kaufmann and Dieter Kabelitz.	Academic Press	2010
		Methods in Microbiology	Oxford	PP 183-193
清野　宏	臨床粘膜免疫学	清野　宏	㈱シナジー	2010
		臨床粘膜免疫学	東京	PP2-722
清野　宏	細胞工学	清野　宏	秀潤社	2011
		細胞工学 「粘膜免疫システム」	東京	PP342-409

研究分担者：紅露　拓

著者名	論文タイトル名	書籍全体の編集者名 書籍名	出版社名 出版地	出版年 ページ
紅露　拓、高津聖志	IL-5による自然免疫制御—B-1細胞と好酸球	平野俊夫、村上正晃	医歯薬出版株式会社	2010
		医学のあゆみサイトカインと疾患—あらたな病態モデルから治療へ	東京都	458-463

V．　研究成果の刊行物・別冊
（主なもの）

PNAS PNAS PNAS

Secretory IgA-mediated protection against *V. cholerae* and heat-labile enterotoxin-producing enterotoxigenic *Escherichia coli* by rice-based vaccine

Daisuke Tokuhara[a,1], Yoshikazu Yuki[a,1], Tomonori Nochi[a], Toshio Kodama[b], Mio Mejima[a], Shiho Kurokawa[a], Yuko Takahashi[a], Masanobu Nanno[c], Ushio Nakanishi[a], Fumio Takaiwa[d], Takeshi Honda[b], and Hiroshi Kiyono[a,2]

[a]Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan; [b]Department of Bacterial Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; [c]Yakult Central Institute for Microbiological Research, Tokyo 186-8650, Japan; and [d]Transgenic Crop Research and Development Center, National Institute of Agrobiological Sciences, Tsukuba 305-8602, Japan

Edited* by Rino Rappuoli, Novartis Vaccines, Siena, Italy, and approved April 8, 2010 (received for review December 7, 2009)

Cholera and enterotoxigenic *Escherichia coli* (ETEC) are among the most common causes of acute infantile gastroenteritis globally. We previously developed a rice-based vaccine that expressed cholera toxin B subunit (MucoRice-CTB) and had the advantages of being cold chain–free and providing protection against cholera toxin (CT)–induced diarrhea. To advance the development of MucoRice-CTB for human clinical application, we investigated whether the CTB-specific secretory IgA (SIgA) induced by MucoRice-CTB gives longstanding protection against diarrhea induced by *Vibrio cholerae* and heat-labile enterotoxin (LT)–producing ETEC (LT-ETEC) in mice. Oral immunization with MucoRice-CTB stored at room temperature for more than 3 y provided effective SIgA-mediated protection against CT- or LT-induced diarrhea, but the protection was impaired in polymeric Ig receptor–deficient mice lacking SIgA. The vaccine gave longstanding protection against CT- or LT-induced diarrhea (for ≥6 months after primary immunization), and a single booster immunization extended the duration of protective immunity by at least 4 months. Furthermore, MucoRice-CTB vaccination prevented diarrhea in the event of *V. cholerae* and LT-ETEC challenges. Thus, MucoRice-CTB is an effective long-term cold chain–free oral vaccine that induces CTB-specific SIgA-mediated longstanding protection against *V. cholerae*- or LT-ETEC–induced diarrhea.

cholera toxin B subunit | mucosal vaccine | oral vaccine | plant-made vaccine | MucoRice

Cholera is an acute diarrheal disease leading to death by severe dehydration without appropriate treatment, especially in developing countries (1). Cholera toxin (CT), produced by *Vibrio cholerae*, consists of a B-subunit pentamer (i.e., CTB) and a single A subunit (i.e., CTA) (2). Diarrhea in cholera is induced by the elevation of intracellular cAMP levels in the intestinal epithelial cells by CTA with ADP ribosyltransferase activity after the binding of CT to GM1 ganglioside, expressed on the epithelial cells, via CTB (2). One of the current oral cholera vaccines, Dukoral, consists of recombinant CTB (rCTB) and whole cells of killed *V. cholerae* (CTB-WC) and is the one that has been used the most extensively worldwide (3). The oral CTB-WC vaccine induces both *V. cholerae*- and CTB-specific immune responses, and past epidemiological studies have clearly shown that it reduces the development of diarrhea by 55% to 85% (3, 4). We recently developed a rice-based cholera vaccine expressing CTB (MucoRice-CTB). This vaccine has the advantages of being suited to long-term storage without the need for a cold chain (>1.5 y), and delivery of the vaccine antigen is needle- and syringe-free (5).

To advance the development of MucoRice-CTB for human clinical application, several key issues remain resolved, despite the promising results obtained in our murine studies (5, 6). First, it is necessary to assess the immunogenicity of MucoRice-CTB in nonhuman primates. Our recent study demonstrated that oral MucoRice-CTB can effectively induce antigen-specific neutralizing antibody responses in nonhuman primates (7). Second, despite the generally accepted concept that mucosal vaccine induces antigen-specific secretory IgA (SIgA) production, thus providing a first line of specific defense against mucosal infectious diseases, there is no direct evidence that the CTB-specific SIgA production induced by MucoRice-CTB is essential for protection against CT-induced diarrhea. The fact that nonhuman primates have preexisting protective intestinal immunity and do not develop CT-induced diarrhea (7) makes it uncertain whether MucoRice-CTB–induced CTB-specific SIgA can in fact prevent diarrhea in these animals. Therefore, it is essential to elucidate the significance of the CTB-specific SIgA production induced by MucoRice-CTB in mice. Third, although several oral CTB vaccines have demonstrated the induction of protective immunity against CT-induced diarrhea in mice (5, 8), it remains unclear whether CTB-specific intestinal SIgA responses, including those induced by oral MucoRice-CTB, can protect against diarrhea induced by live *V. cholerae*. Finally, minimal information on the duration of the protective immunity induced by oral MucoRice-CTB vaccine is currently available. To clarify these unresolved key issues, we aimed to (*i*) directly demonstrate whether antigen-specific SIgA production induced by oral MucoRice-CTB is a critical element in protective immunity against CT-induced diarrhea in mice; (*ii*) examine the longevity of MucoRice-CTB–induced primary antigen–specific neutralizing humoral immunity and the effects of oral boosters; and (*iii*) elucidate in vivo whether oral MucoRice-CTB–induced antigen-specific mucosal IgA responses provide protective immunity against diarrhea caused by *V. cholerae*.

In addition to *V. cholerae*, enterotoxigenic *Escherichia coli* (ETEC) is a major cause of bacterial diarrhea in developing countries (9, 10) and a leading cause of travelers' diarrhea in developed countries (11). ETEC produces heat-stable enterotoxin (ST) and/or heat-labile enterotoxin (LT) (2). LT is found in approximately two thirds of cases of ETEC-induced diarrhea (12–14). In addition, previous studies have shown that anti-LT immunity protects against ETEC-induced diarrhea in human (15–17). LT is structurally and biologically similar to CT (2, 18), and several studies have demonstrated cross-protective immunity between CT and LT (19–21). It was therefore an obvious and important question to address whether CT-specific mucosal IgA induced by oral MucoRice-CTB vaccine could provide cross-protective immunity against LT-induced

Author contributions: D.T., Y.Y., T.N., T.H., and H.K. designed research; D.T., Y.Y., T.N., T.K., M.M., S.K., and Y.T. performed research; T.K., M.N., U.N., F.T., and T.H. contributed new reagents/analytic tools; D.T. and Y.Y. analyzed data; and D.T., Y.Y., T.N., and H.K. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

[1]D.T. and Y.Y. contributed equally to this work.

[2]To whom correspondence should be addressed. E-mail: kiyono@ims.u-tokyo.ac.jp.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.0914121107/-/DCSupplemental.

diarrhea and, if so, whether it could also provide protection against diarrhea induced by LT-producing ETEC (LT-ETEC).

We demonstrated here that the CTB-specific SIgA response induced by oral MucoRice-CTB is solely responsible for antibody-mediated, cross-protective, long-term immunity against LT- and CT-induced diarrhea; this effectiveness was further extended to *V. cholerae*- and LT-ETEC–induced diarrhea in vivo. These findings enforce the attractiveness and advantages of the cold chain- and needle- and syringe-free MucoRice system and should enable the development of an innovative oral vaccination strategy against *V. cholerae* and LT-ETEC.

Results

MucoRice-CTB–Induced Protection Against CT-Induced Diarrhea Is Impaired in Polymeric Ig Receptor–KO Mice. To examine whether induction of the secretory form of CTB-specific IgA by oral MucoRice-CTB vaccination is a critical element in protection against CT-induced diarrhea, we compared polymeric Ig receptor (pIgR)–KO and WT mice vaccinated orally with MucoRice-CTB. We thus clarified the direct role of CTB-specific SIgA in providing protection against CT-induced diarrhea. MucoRice-CTB–immunized pIgR-KO mice, which lacked the formation and transepithelial transport of SIgA, had significantly lower ($P = 0.0001$) antigen-specific mucosal IgA levels in their intestinal secretions than did immunized WT mice (Fig. 1*A*). In contrast, lack of CTB-specific SIgA formation and transport caused a significant increase ($P < 0.0001$ vs. immunized WT mice) in the serum CTB-specific IgA level in oral MucoRice-CTB–immunized pIgR-KO mice, whereas the antigen-specific serum IgG titer was comparable to that of WT mice orally immunized with MucoRice-CTB (Fig. 1*A*). When the frequency of CTB-specific IgA antibody-forming cells (AFCs) was examined in the small intestinal lamina propria (LP), significantly more antigen-specific IgA AFCs were found in MucoRice-CTB–immunized pIgR-KO mice ($P = 0.0007$) than in MucoRice-CTB–immunized WT mice (Fig. 1*B*). Our finding of large numbers of antigen-specific IgA AFCs in immunized pIgR-KO mice is compatible with the results of a previous study that found a marked accumulation of IgA in the intestinal LP of pIgR-KO mice by immunohistochemical analysis (22). When these two groups (pIgR-KO and WT), of MucoRice-CTB–vaccinated mice were orally challenged with a native form of CT, the immunized WT mice showed protection against CT-induced diarrhea, whereas the pIgR-KO mice developed severe diarrhea ($P = 0.002$ vs. immunized WT mice), despite the presence of high titers of antigen-specific serum IgG and



Fig. 1. Critical role of antigen-specific SIgA induced by oral MucoRice-CTB vaccine in protection against CT- or LT-induced diarrhea. Cross-protective antigen-specific antibody immune responses were examined and compared among oral MucoRice-CTB (100 mg)–immunized WT mice (gray columns), oral MucoRice-CTB–immunized pIgR-deficient mice (white columns), and WT rice–fed WT mice (black columns). (*A*) Antibody immune responses against CTB. (*B*) ELISPOT assay. Frequency of CTB-specific IgA AFCs in intestinal LP was elevated in MucoRice-CTB–immunized WT mice (gray squares), and markedly increased in MucoRice-CTB–immunized pIgR-deficient mice (white triangles), but absent in WT rice–fed mice. (*C*) Oral CT challenge (20 μg). WT rice–fed WT mice (black column) or MucoRice-CTB–immunized pIgR-deficient mice (white column) had severe fluid accumulation, whereas MucoRice-CTB–immunized WT mice (gray column) had markedly reduced fluid accumulation. (*D*) Cross-protective specific serum IgG and fecal IgA against LTB were induced in mice by oral MucoRice-CTB immunization. (*E*) Oral LT challenge: 30 μg of LT was intragastrically administered to mice. WT rice–fed WT mice (black column) or MucoRice-CTB–immunized pIgR-deficient mice (white column) had severe fluid accumulation, whereas MucoRice-CTB–immunized WT mice (gray column) had markedly reduced fluid accumulation. Data represent means ± SD. *$P < 0.0001$.

IgA and the increased numbers of CTB-specific IgA AFCs in the intestinal LP (Fig. 1*C*). Taken together, these findings directly demonstrated that CTB-specific SIgA, and not serum antibodies, was responsible for humoral protective immunity against CT-induced diarrhea.

We next clarified the essential role of CTB-specific SIgA by examining whether oral MucoRice-CTB gave protection superior to that of parenteral CTB immunization against CT-induced diarrhea. Comparison of the quantity and quality of antigen-specific protective immune responses, including diarrhea protection, between oral MucoRice-CTB and parenteral rCTB revealed that oral MucoRice-CTB induced the production of not only CTB-specific serum IgG but also CTB-specific SIgA, whereas the injectable vaccine induced only CTB-specific serum IgG production (Fig. S1*A*). The parenterally induced CTB-specific IgG response did not provide sufficient protection against CT-induced diarrhea, but oral MucoRice-CTB offered full protection because of the induction of antigen-specific SIgA responses (Fig. S1*B*). These findings suggest that MucoRice-CTB oral immunization provides protection superior to that from parenteral CTB immunization against experimental cholera because it induces significantly greater production of antigen-specific SIgA (P = 0.008).

MucoRice-CTB Induces Cross-Protective Immunity Against LT. Another important aspect of the antigen-specific SIgA induced by oral MucoRice-CTB was the demonstration of cross-reactivity with ETEC-associated toxin (i.e., LT; Fig. 1*D*). Cross-protective serum IgG and fecal SIgA production against B subunit of LT (LTB) was significantly greater (P = 0.002 and P = 0.001, respectively) in WT mice immunized with MucoRice-CTB than in unimmunized mice. Oral MucoRice-CTB vaccination induced SIgA-mediated protective immunity against LT-induced diarrhea in WT mice, whereas MucoRice-CTB–immunized pIgR-KO mice failed to form cross-reactive SIgA and thus developed severe diarrhea after oral challenge with LT (Fig. 1*E*). These findings demonstrated another advantage of the SIgA responses induced by MucoRice-CTB, whereby oral vaccination induced cross-reactive SIgA-mediated immunity against LT-induced diarrhea.

Long-Lasting Protection and Boosting Effects of MucoRice-CTB Vaccination Against CT-Induced Diarrhea. The duration or memory of protective immunity is another critical issue for further advancement of MucoRice-CTB as a new form of oral vaccine. After three or four primary oral immunizations with MucoRice-CTB, the extent of protective immunity was monitored over a 6-month period. High titers of CTB-specific serum IgG and IgA were maintained during the 6 months (Fig. 2*A*). Levels of CTB-specific SIgA were also high in intestinal secretions, although they gradually decreased during the 6 months: the antibody titer at 6 months was half of the level 1 week after the final immunization (Fig. 2*A*). When a single oral booster MucoRice-CTB vaccination was given, the declining antigen-specific SIgA levels bounced back to high titers within 1 week. The numbers of CTB-specific IgA AFCs in the intestinal LP were thus rapidly and markedly increased after the booster immunization to levels significantly ($P < 0.0001$) greater than in unvaccinated mice or in vaccinated mice 1 or 24 weeks after the last of the first four doses of the primary immunization (Fig. 2*B*). Even though the levels of antigen-specific SIgA had declined by 6 months, partial protection against CT challenge was maintained (Fig. 2*C*). A single oral booster dose of MucoRice-CTB resulted in the recovery of full protection against CT challenge (Fig. 2*C*) and maintained effective protective mucosal immunity for at least another 4 months (Fig. 2*A*). These findings suggested that a CTB-specific-memory type of mucosal SIgA response was induced by oral vaccination with MucoRice-CTB.



Fig. 2. Induction of long-term SIgA-mediated immunity against toxin by oral MucoRice-CTB vaccine. We examined the longevity of antigen-specific antibody immune responses and protection against CT-induced diarrhea, as well as the boosting effect of oral MucoRice-CTB. Booster (100 mg of MucoRice-CTB containing 150 μg CTB) was administered 24 weeks after the final immunization. One week later, boosted immune responses were measured and monitored for the next 16 weeks. (*A*) Antibody titers were simultaneously evaluated. (*B*) ELISPOT. Numbers of CTB-specific IgA AFCs in the intestinal LP of each mouse were evaluated over the same time period. (*C*) Oral CT challenge. Mice were immunized and challenged over the same time course as described earlier. Data represent means ± SD. *$P < 0.0001$.

MucoRice-CTB Induces Protection Against *V. cholerae*– and LT-ETEC–Induced Diarrhea. We used an intestinal loop bacterial challenge to examine whether oral MucoRice-CTB–induced antigen-specific SIgA provided protection against *V. cholerae*–induced diarrhea. When the small intestines of mice orally vaccinated with MucoRice-CTB were exposed to *V. cholerae*, almost full protection was achieved (Fig. 3). In contrast, most of the mice orally immunized with WT rice developed *V. cholerae*–induced diarrhea. Our preliminary results had shown that although the incidence of diarrhea was low (20–40%) when naive murine intestines were exposed to LT-ETEC, the incidence was sufficient for us to establish the LT-ETEC in vivo challenge model. The incidence of diarrhea was compatible with that in a previous study, which found that 34% of loops tested by using ETEC strains isolated from diarrheic infant mice showed signs of diarrhea (23). Under our experimental conditions, oral MucoRice-CTB vaccination imparted significantly ($P = 0.04$) greater resistance to LT-ETEC challenge than did oral administration of WT rice (Fig. 3). Our findings thus directly demonstrated that oral MucoRice-CTB could induce cross-protective immunity against *V. cholerae*– and LT-ETEC–induced diarrhea.

Discussion

These findings demonstrated the critical role of antigen-specific SIgA responses induced by oral MucoRice-CTB vaccine in long-term cross-protective immunity against *V. cholerae*– and LT-ETEC–induced diarrhea. Thus, these results further reinforced the attractive features of MucoRice-CTB as a new-generation oral vaccine. Our results demonstrated that oral MucoRice-CTB–induced SIgA is a critical protective element in the neutralization of CT- and LT-induced diarrhea. Our comparative study of the quality of oral MucoRice-CTB–induced intestinal SIgA levels and parenteral CTB–induced serum IgG levels showed that the former mucosal immunity plays a more critical role than the latter systemic immunity in protection against CT- and LT-induced diarrhea (Fig. S1). Although previous studies have demonstrated the important role of CT-specific SIgA in protection against CT-induced diarrhea (24, 25), our study shows that induction of CTB-specific SIgA is sufficient for protection against CT-induced diarrhea. When naive mice were orally immunized with CT, production of CTA-specific intestinal SIgA was much lower than that of CTB-specific intestinal SIgA (Fig. S2). In our separate study, we demonstrated that both CTA and CTB are necessary for CHO cells to exhibit the toxic effects of CT (Fig. S3). However, in the inhibition of the CT-induced elongation, CTB- but not CTA-specific antibody alone was sufficient (Fig. S3). These results further indicate that CTB-specific SIgA plays a critical role in protection against CT-induced diarrhea.



	V. cholerae		LT-ETEC	
	n	Number of mice with positive loop (%)	n	Number of mice with positive loop (%)
WT rice	7	6 (85)	20	7 (35)
MucoRice	7	1 (14)[a]	14	1 (7)[b]

Fig. 3. Oral MucoRice-CTB–induced antigen-specific SIgA provides cross-protective immunity against *V. cholerae*– and LT-ETEC–induced diarrhea. Murine intestinal loop assay using *V. cholerae* (10^9 cells) and LT-ETEC (10^9 cells) was executed in WT mice orally immunized with MucoRice-CTB or WT rice. Unlike WT rice, oral MucoRice-CTB vaccination markedly reduced the incidence of *V. cholerae*– and LT-ETEC–induced diarrhea. When the ratio of fluid to length was greater than 30 μL/cm, the intestinal loop was considered positive for diarrhea. The positive loop ratio is shown in the parentheses as a percentage of the total number of mice examined. (*a*) $P = 0.004$ compared with WT rice–fed mice. (*b*) $P = 0.04$ compared with WT rice–fed mice.

The essential role of CTB-specific SIgA was directly demonstrated by our oral vaccination of pIgR-deficient mice with MucoRice-CTB. In pIgR-deficient mice, the lack of formation in the intestinal LP of CTB-specific SIgA with cross-neutralizing activity, and thus the lack of its secretion into the lumen, resulted in loss of protection against CT- or LT-induced diarrhea (Fig. 1). The critical role of CTB-specific SIgA in the neutralization of CT was further demonstrated by in vitro assay (Fig. S4). When SIgA was purified from intestinal secretions of mice orally immunized with MucoRice-CTB and tested in the two standard in vitro neutralization assays (CHO cell elongation assay and GM1 binding assay), the purified intestinal CTB-specific SIgA effectively neutralized CT. Whereas previous studies have demonstrated the neutralizing ability of CTB-specific serum antibodies in vitro (5, 8), our study directly demonstrates that intestinal CTB-specific SIgA is responsible for humoral immunity in preventing CT- and live gut pathogen–induced diarrhea (Fig. S4).

As a practical aspect of vaccination in the clinical setting, induction of immune memory is another key factor in strategic approaches to the development of a new generation of vaccines against cholera. Our recent and separate study in nonhuman primates showed that the level of CTB-specific humoral immunity was maintained 6 months after oral primary immunization with MucoRice-CTB (7). Our study further provided evidence that oral MucoRice-CTB vaccination could offer long-term protection, because CT-neutralizing antibodies were maintained over a 6-month period in the systemic and mucosal compartments after the final oral primary immunization in mice. In long-term humoral immunity, long-lived plasma cells and memory B cells are key factors (26). Upon antigen rechallenge, memory B cells expand rapidly and differentiate into plasma cells (26). Our results indicated that immunological memory was induced by oral MucoRice-CTB vaccination; thus a single oral booster immunization at 6 months resulted in a rapid increase in levels of CTB-specific neutralizing SIgA and their additional long-term maintenance. Although we need clinical trials to investigate the effectiveness of oral MucoRice-CTB in inducing memory-type immune responses in humans, extrapolation of the mouse lifespan to that of humans suggests that the long-lasting protective immunity (i.e., 6 months) observed in mice will cause MucoRice-CTB to be of practical use in humans.

Another practical advantage of MucoRice-CTB is our original demonstration that refrigerated storage is not necessary for maintenance of immunogenicity through induction of neutralizing antibodies (5). Our uninterrupted investigation has now further demonstrated that oral immunization with MucoRice-CTB stored at room temperature for more than 3 y induces levels of serum and intestinal CTB-specific antibodies comparable to those induced by fresh harvested MucoRice-CTB (Fig. S5). This ability of cold chain–free MucoRice-CTB to induce long-term immune memory offers a global vaccination strategy by which MucoRice-CTB can be supplied to health care facilities at low cost. It can be conveniently stored without refrigeration, even in rural areas of developing countries where populations regularly suffer from *V. cholerae* infection, for primary and/or booster oral immunization against the infection.

The other important aspect of these results is that oral MucoRice-CTB vaccination induced SIgA-mediated cross-protective immunity against LT- and LT-ETEC–induced diarrhea (Figs. 1 and 3). ETEC is an important cause of acute infantile diarrhea and travelers' diarrhea (9–11), and LT-ETEC is found in approximately two thirds of cases of ETEC-associated diarrhea (12–14). Our results suggest that MucoRice-CTB could therefore be used to control a large proportion of ETEC-induced diarrhea.

Oral MucoRice-CTB induced intestinal SIgA–based protective immunity that could neutralize artificially and acutely inoculated large doses of CT or LT in the intestinal canal. In the oral CT challenge model, a bolus of toxin passes through the intestinal canal in

a short time and induces acute diarrhea (27). In the murine intestinal loop assay, inoculated and proliferated bacteria gradually release small amounts of toxin and induce fluid accumulation in the loop 12 to 18 h after inoculation (27). By using these two related but different in vivo models simultaneously, we demonstrated that MucoRice-CTB is a compelling vaccine for inducing effective SIgA-mediated immunity that can control enterotoxin-mediated clinical signs.

A previous study found that intragastric administration of monoclonal LPS-specific IgA, not but CTB-specific IgA, protects against *V. cholerae*–induced death in neonatal mice (28). This study revealed the important role of anti-LPS antibody as a vibriocidal antibody. Moreover, a new modified killed WC oral cholera vaccine was recently reported to be effective in providing 70% protection over a 2-year period (29). However, early studies have shown that the CTB-WC vaccine is initially more effective than the WC vaccine (85% vs. 58% for the initial 4–6-month period) (3, 4), indicating that the induction of anti-CTB antibody has a substantial protective effect against cholera. We showed here that physiologically and continuously secreted CTB-specific SIgA supplied from the gut mucosal immune system was important in protecting against *V. cholerae*– (and LT-ETEC–) induced diarrhea in vivo. We therefore offer an alternative to WC- or LPS-based vaccines. Furthermore, our prevention of LT-ETEC–induced diarrhea by the induction of cross-protective CTB-specific SIgA is not achieved by the WC cholera vaccine.

Transcutaneous immunization with LT supplied in patch form has recently been reported to be protective against ETEC-induced travelers' diarrhea; the increase in serum LT-specific IgA levels induced is correlated with the mucosal immune response (17). A recent study revealed that transcutaneous immunization induces the activity of Ag-specific IgA-secreting cells expressing CCR9 and CCR10 in the small intestine in a retinoic acid–dependent manner and that cross-talk between the skin and gut immune systems might be mediated by langerin(+) dendritic cells in the mesenteric lymph nodes (30). These results provide supportive evidence that our MucoRice-CTB–induced toxin-specific neutralizing SIgA contributes to the induction of protective immunity against CT-producing *V. cholerae* and LT-ETEC in humans. Oral MucoRice-CTB vaccination effectively induces CTB- and LTB-cross-reactive SIgA that most likely does not block colonization by *V. cholerae* and LT-ETEC but strongly inhibits CT- and LT-induced watery diarrhea, which is the clinical sign of greatest concern in *V. cholerae* and LT-ETEC infections.

Previous studies show that CTB can be used as an antigen delivery vehicle for the induction of oral tolerance, whereas CT can be used as an adjuvant agent and can abrogate oral tolerance (31–33). Enhancement of tolerance has been clearly demonstrated when a protein is coupled to CTB and given orally (31, 32). In contrast, CTB does not induce oral tolerance to itself (33). Because MucoRice-CTB at varying doses (18.75–150 μg) induces antigen-specific immune responses against CTB (7), we consider that the MucoRice-CTB does not induce oral tolerance to the CTB itself. MucoRice expressing CTB-based chimeric protein with a foreign antigen (MucoRice-CTB-Ag) may become an effective delivery vehicle for the induction of oral tolerance to the antigen. In fact, rice seed containing CTB-fused allergen-specific T cell epitopes induces oral tolerance to allergen more efficiently than does rice expressing allergen-specific epitopes alone (34). Moreover, conjugation of an antigen to CTB can induce the proliferation of regulatory T cells (35, 36); this may be the mechanism by which the above mentioned rice seed containing the CTB-fused epitopes effectively induces oral tolerance.

In summary, our study has further elucidated the mechanism and practical attractiveness of oral MucoRice-CTB vaccine, as well as its immunological effectiveness. This vaccine is capable of inducing long-term CTB- and LTB-cross-reactive mucosal IgA-mediated protective immunity against *V. cholerae*– and LT-ETEC–induced diarrhea. This feature will be useful in vaccine strategies against outbreaks of not only *V. cholerae* but also LT-ETEC, both in the inhabitants of developing countries and in at-risk travelers in developed countries.

Methods

Animals. Female BALB/c mice (4–7 weeks old) and pIgR KO mice on a BALB/c background were used (22). All of the mice were housed with ad libitum food and water on a standard 12 h/12-h light/dark cycle. All experiments were performed in accordance with the Guidelines for Use and Care of Experimental Animals and approved by the Animal Committee of the Institute of Medical Science of the University of Tokyo.

Vaccine. MucoRice-CTB, a rice-expressed CTB with a KDEL signal at the C-terminal of CTB, was produced as reported previously (5). Rice seeds that had been stored at room temperature for more than 3 y were ground to a fine powder in a Multi-Beads Shocker (Yasui Kikai).

Immunization. Eight-week-old female mice (six per group) were orally given 100 mg of powdered MucoRice-CTB containing 150 μg of CTB by stomach tube a total of three or four times at 2-week intervals (5). To evaluate vaccine booster effects, mice (six per group) were orally given one dose of MucoRice-CTB 6 months after the final primary immunization. In the control group, mice (six per group) were orally given 100 mg of powdered nontransgenic WT rice in distilled water.

ELISA. Serum and fecal extracts were collected 1, 4, 12, 16, and 24 weeks after final oral immunization to assess CTB- and/or LTB-specific antibody immune responses by ELISA. Coating antigens [5 μg/mL rCTB and/or recombinant LTB (rLTB)] were used, as previously described (5). rCTB was expressed in *Bacillus brevis* and purified by using immobilized galactose (Pierce) (5, 37). rLTB was expressed in *Brevibacillus choshinensis* and purified by using immobilized galactose (Pierce) as previously described, with some modification (38).

Enzyme-Linked Immunospot Assay. CTB- and LTB-specific IgA AFCs in the small intestinal LP were evaluated by using an enzyme-linked immunospot (ELISPOT) assay as previously described (39). LP mononuclear cells were isolated as previously described and processed on MultiScreen$_{HTS}$ 96-well filtration plates (Millipore) coated with 5 μg/mL rCTB or rLTB (39).

Neutralizing Assay. An in vivo oral CT or LT challenge test was used as described previously (5). After being fasted for 12 h, mice (12 per group) were orally challenged with 20 μg of CT (List Biological Laboratories) or 30 μg of LT purified from a human ETEC strain in our laboratory. Nine to 12 hours after the challenge, the mice were killed. The small intestine and colon were removed for clinical diarrhea observation and collection of intestinal contents. After centrifugation of the samples, the volume of intestinal water was measured (5).

Bacterial Challenge. An in vivo bacterial challenge, the ligated intestinal loop test, was performed based on a published method, with some modification (28). The bacterial strains used were obtained from the Research Institute for Microbial Diseases (RIMD) Bacterial Culture Collection at Osaka University. RIMD 2203363 is a typical *V. cholerae* strain (El Tor O1 Inaba) of human origin and has been confirmed to secrete CT. RIMD 0509328 is an ETEC strain of human origin confirmed to secrete LT only, without ST. This LT-ETEC strain was selected from among 27 LT-ETEC strains by a reverse-passive latex agglutination test (Denka Seiken) as producing large amounts of LT. *V. cholerae* and LT-ETEC microorganisms were grown overnight in Trypticase Soy Broth (TSB; Becton Dickinson) at 37 °C. *V. cholerae* and LT-ETEC from these cultures were further grown in TSB for 3 h at 30 °C and 4 h at 37 °C, respectively. Bacteria were washed twice in PBS solution to remove secreted toxin and diluted to a concentration of 10^{10} organisms/mL in TSB. Colony-forming units of *V. cholerae* and LT-ETEC were quantified on thiosulfate–citrate–bile salt–sucrose agar plates and on TSB agar plates, respectively.

For the challenge experiments, BALB/c female mice were starved for 36 h but had free access to water. The mice were then anesthetized and subjected to laparotomy. The small intestine was withdrawn and ligated at a distance of approximately 6 cm from the stomach. One loop of 4 to 6 cm was made in each animal. A dose of 10^9 *V. cholerae* cells or LT-ETEC cells in 0.2 mL TSB was delivered into the mouse intestinal loop by syringe. After 12 to 18 h, the challenged mice were killed and the abdomen was reopened. The loops were removed for assessment of the length of each one and the volume of accumulated fluids. The extent of fluid accumulation was expressed as a ratio of the volume (in mL) of accumulated fluid per length (in cm) of the loop. The results were considered positive when the ratio of fluid to length was more than 30 μL/cm (as determined in preliminary studies). Control experiments with 20 normal mice revealed that injection of 0.2 mL of sterile TSB alone into the loop caused no positive reaction in terms of fluid accumulation.